Teprenone
Based on 5 publication(s) in Google Scholar
Teprenone is an anti-ulcer agent, and works as an inducer of heat shock proteins (HSPs).
For research use only. We do not sell to patients.
- Purity: 99.31%
- CAS No.: 6809-52-5
- Formula: C23H38O
- Molecular Weight:330.55
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Teprenone
More-
WB
Biological Activity
|
HSP |
Teprenone is an inducer of HSPs. Teprenone (Geranylgeranylacetone, 1 μM) significantly prevents ethanol-induced exfoliation, and reduces lactate dehydrogenase (LDH) release in gastric mucosal cells. Teprenone (1 μM) gradually increases HSC70 level, and rapidly accumulates the stress-inducible HSP90, HSP70, and HSP60 concentrations within 30-60 min. Teprenone also activates the heat shock factor 1[1].
Teprenone (0-20 μM) slightly increases human umbilical vein endothelial cell (HUVEC) viability following irradiation (IR). Teprenone (10 μM) exhibits no effects on HUVEC migration and invasion, but enhances HUVEC tube formation and wound healing both with and without IR. Teprenone (10 μM) also promotes angiogenesis by inducing VEGF and eNOS expression in HUVECs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Teprenone (200 mg/kg daily) induces HSP72 in retinal ganglion cells (RGCs) from rat retinas. Teprenone significantly reduces the loss of RGCs (evaluated after intraocular pressure (IOP) elevation), lessens optic nerve damage, decreases the number of TUNEL-positive cells in the RGC layer, and increases HSP72 in a rat model of glaucoma[2].
Teprenone (200 mg/kg, p.o.) shows protective effect on radiation-induced intestinal injury in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 6809-52-5
-
Appearance Liquid (Density: 0.9081 g/cm3)
-
Molecular Weight 330.55
-
Formula C23H38O
-
Color Colorless to light yellow
-
SMILES
CC(CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=O
-
Synonyms
Geranylgeranylacetone
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
HSPA8 dampens SCAP/INSIG split and SREBP activation by reducing PKR-mediated INSIG phosphorylation. [Abstract]2025 Feb 19;44(3):115339. PMID: 39977267 -
Phytother Res
2018 Jul;32(7):1320-1331. PMID: 29516568
Teprenone purchased from MedChemExpress. Usage Cited in: Phytother Res. 2018 Jul;32(7):1320-1331. [Abstract]
Panc-28 cells are treated with GGA (20 μM) for 48 hr and the expression of HSPA8 is determined using western blot.
-
Chem Biol Interact
Geranylgeranylacetone, an inducer of heat shock protein 70, attenuates pulmonary fibrosis via inhibiting NF-κB/NOX4/ROS signalling pathway in vitro and in vivo. [Abstract]2023 Sep 1:382:110603. PMID: 37307957 -
Int Immunopharmacol
Geranylgeranylacetone mitigates sepsis-associated intestinal injury through CHIP-dependent anti-inflammation and anti-oxidative effect. [Abstract]2024 May 23:135:112263. PMID: 38788444 -
Cell Stress Chaperones
Overexpression of heat shock protein 70 inhibits epithelial-mesenchymal transition and cell migration induced by transforming growth factor-β in A549 cells. [Abstract]2021 May;26(3):505-513. PMID: 33598875
Solvent & Solubility
DMSO : 100 mg/mL (302.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (151.26 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Human umbilical vein endothelial cells (HUVECs) are seeded onto 48-well plates at a density of 1 × 102 cells/well before Teprenone and/or radiation treatment. Cell viability is determined at 48 h after treatment using 0.5 mg/mL MTT solution in serum-free media. This solution is incubated with the cells for 2 h in the 37°C humidified atmosphere containing 5% CO2. Then, the MTT solution is removed, and the cells are dissolved in 100 µL of DMSO. Optical densities of the supernatants are measured at 540 nm with an ELISA spectrophotometer[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Male Wister strain rats weighing approximately 250 g are individually housed in wire-mesh cages in a room maintained at 23°C on a 12-hour light-dark cycle. Rats are allowed free access to a standard laboratory chow. Teprenone (200 mg/kg; as emulsion with 5% gum arabic and 0.008% α-tocopherol) or vehicle (5% gum arabic emulsion containing 0.008% α-tocopherol) is given orally in a volume of 5 mL/kg through a metal tubing attached to a 6-mL syringe. Two hours later, rats are placed in restraint cages and then vertically immersed in water at 23°C to the level of the xyphoid process. The rats are killed by decapitation at the indicated times[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hirakawa T, et al. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology. 1996 Aug;111(2):345-57. [Content Brief]
[2]. Caprioli J, et al. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Trans Am Ophthalmol Soc. 2003;101:39-50; discussion 50-1. [Content Brief]
[3]. Han NK, et al. Geranylgeranylacetone Ameliorates Intestinal Radiation Toxicity by Preventing Endothelial Cell Dysfunction. Int J Mol Sci. 2017 Oct 7;18(10). [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.0253 mL | 15.1263 mL | 30.2526 mL | 75.6315 mL |
| 5 mM | 0.6051 mL | 3.0253 mL | 6.0505 mL | 15.1263 mL | |
| 10 mM | 0.3025 mL | 1.5126 mL | 3.0253 mL | 7.5632 mL | |
| 15 mM | 0.2017 mL | 1.0084 mL | 2.0168 mL | 5.0421 mL | |
| 20 mM | 0.1513 mL | 0.7563 mL | 1.5126 mL | 3.7816 mL | |
| 25 mM | 0.1210 mL | 0.6051 mL | 1.2101 mL | 3.0253 mL | |
| 30 mM | 0.1008 mL | 0.5042 mL | 1.0084 mL | 2.5211 mL | |
| 40 mM | 0.0756 mL | 0.3782 mL | 0.7563 mL | 1.8908 mL | |
| 50 mM | 0.0605 mL | 0.3025 mL | 0.6051 mL | 1.5126 mL | |
| 60 mM | 0.0504 mL | 0.2521 mL | 0.5042 mL | 1.2605 mL | |
| 80 mM | 0.0378 mL | 0.1891 mL | 0.3782 mL | 0.9454 mL | |
| 100 mM | 0.0303 mL | 0.1513 mL | 0.3025 mL | 0.7563 mL |